Durata Therapeutics confirms FDA approval of Dalvance, shares halted

|About: Durata Therapeutics (DRTX)|By:, SA News Editor

Durata Therapeutics (DRTX) says the FDA has approved its Dalvance antibiotic for the treatment of patients with acute bacterial skin and skin structure infections.

Dalvance is the first drug with the qualified infectious disease product designation to receive FDA approval.

A March FDA advisory panel approval also had given a favorable review to a rival product from Cubist Pharmaceuticals (CBST); the FDA is set to rule on the CBST drug shortly.

DRTX shares halted.